Aligos therapeutics to present data on its liver disease programs at the european association for the study of the liver (easl) congress 2023

South san francisco, calif., june 07, 2023 (globe newswire) -- aligos therapeutics, inc. (nasdaq: algs), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that the company will present seven posters collectively highlighting data on its liver disease programs at the european association for the study of the liver (easl) congress 2023, taking place in vienna, austria, june 21 – 24, 2023.
ALGS Ratings Summary
ALGS Quant Ranking